Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
A Florida couple is suing their fertility clinic after discovering the baby girl born via IVF is not genetically related to them, sparking a complex legal and ethical battle over parentage and clinic accountability.
Advocate Health, the nation's third-largest nonprofit health system, is investing over $800 million in enhanced compensation and benefits for its 165,000+ employees, raising its minimum wage and expanding tuition aid, mental health support, and paid volunteer time.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Eli Lilly announces a massive new manufacturing facility in Pennsylvania, part of a strategic pivot by major drugmakers to onshore production amid trade tensions and soaring demand for weight-loss drugs.
Facing a new U.S. threat of tariffs on nations supplying oil to Cuba, Mexican President Claudia Sheinbaum pledges to pursue diplomatic channels and seek alternatives to avert a potential humanitarian crisis on the island, while safeguarding Mexico's own economic interests.
The Rafah border crossing between Gaza and Egypt is set to partially reopen Sunday, marking a fragile step in the U.S.-brokered ceasefire. While offering a lifeline for medical evacuees and displaced families, the operation will be tightly controlled by Israeli, Egyptian, and EU officials, with significant restrictions on the movement of people and goods.
Secretary-General Antonio Guterres warns in a confidential letter that the United Nations faces a severe cash crunch, driven by unpaid dues and restrictive budget rules, threatening its operational viability by mid-year.
Eli Lilly bolsters its long-term growth strategy through two new R&D partnerships and a key regulatory milestone for an ovarian cancer drug, signaling a strategic push beyond its blockbuster diabetes and obesity treatments.
ARK Invest's founder capitalized on recent market weakness to increase holdings in three of her flagship disruptive innovation picks, signaling continued conviction despite sector volatility.
Amid market volatility, these three companies offering yields above 4% present a compelling case for income-focused investors, backed by strategic pivots and resilient business models.
Fresh Israeli military actions in central and southern Gaza have resulted in multiple casualties, testing the durability of a months-long, U.S.-brokered truce and hindering critical aid flows.
President Trump's laissez-faire stance on the dollar's slide to a four-year low risks backfiring on his core promise to lower living costs, as analysts warn a weak currency could fuel inflation and thwart rate cuts.
Despite a premium valuation, AMD is positioning itself as a key challenger in the AI chip race, betting big on integrated data center systems to capture surging demand.
At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.
The Horatio Alger Award bestowed upon ResMed founder Dr. Peter Farrell underscores the company's decades-long leadership in sleep and respiratory care, bringing its financial performance and competitive strategy into sharper focus for investors.
Once the undisputed leader in connected fitness, Peloton Interactive is navigating a critical business reset. Faced with declining revenue, subscriber churn, and a shifting market, the company is trading rapid expansion for a strategy focused on cost control and stabilization. The core question for investors is whether its brand and ecosystem can sustain a profitable future.
Goldman Sachs has upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy, raising its price target to $142. The firm highlights the company's pivotal role in next-generation cancer treatments, including immuno-oncology and antibody-drug conjugates (ADCs), as a major catalyst for future growth.
